Published Online
on August 14, 2006

A more recent version of this article appeared on August 29, 2006

This Article Full Text (PDF) All Versions of this Article: 114/9/921    most recent CIRCULATIONAHA.106.613588v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suttorp, M. J. Articles by Mast, E. G. Search for Related Content PubMed PubMed Citation Articles by Suttorp, M. J. Articles by Mast, E. G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Antibiotics Related Collections Coronary circulation Catheter-based coronary interventions: stents Restenosis Related Article

Submitted on January 14, 2006
Revised on June 5, 2006
Accepted on June 30, 2006

Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II). A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions

Maarten J. Suttorp MD, PhD^*, Gert J. Laarman MD, PhD, Braim M. Rahel MD, PhD, Johannes C. Kelder MD, Mike A.R. Bosschaert MD, Ferdinand Kiemeneij MD, PhD, Jur M. ten Berg MD, PhD, Egbert T. Bal MD, Benno J. Rensing MD, PhD, Frank D. Eefting MD, and E. Gijs Mast MD

From the Departments of Interventional Cardiology (M.J.S., B.M.R., J.M.t.B., E.T.B., B.J.R., F.D.E., E.G.M.) and Research and Statistics (J.C.K., M.A.R.B.), St Antonius Hospital Nieuwegein, Nieuwegein; and Department of Interventional Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam (G.J.L., F.K.), the Netherlands.

^* To whom correspondence should be addressed. E-mail: maarten.suttorp{at}inter.nl.net.

Background--Sirolimus-eluting stents markedly reduce the risk of restenosis compared with bare metal stents. However, it is not known whether there are differences in effectiveness between bare metal and sirolimus-eluting stents in patients with total coronary occlusions.

Methods and Results--In a prospective, randomized, single-blind, 2-center trial, we enrolled 200 patients with total coronary occlusions: Half (n=100) were randomly assigned to receive bare metal BxVelocity stents and half (n=100) to receive sirolimus-eluting Cypher stents. The primary end point was angiographic binary in-segment restenosis rate at 6-month follow-up. Secondary end points were a composite of major adverse cardiac events, target vessel failure, binary in-stent restenosis rate, in-stent and in-segment minimal lumen diameter, percent diameter stenosis, and late luminal loss at 6-month follow-up. The sirolimus stent group showed a significantly lower in-stent binary restenosis rate of 7% compared with 36% in the bare metal stent group (P<0.001). The in-segment binary restenosis rate was 11% in the group receiving a sirolimus stent versus 41% in the bare metal stent group (P<0.0001), resulting in a target lesion revascularization rate of 4% in the sirolimus group versus 19% in the bare metal group (P<0.001). Patients who received the drug-eluting stent also had significantly lower rates of target vessel revascularization, target vessel failure, and all major adverse cardiac events.

Conclusions--In patients with total coronary occlusions, use of the sirolimus-eluting stents are superior to the bare metal stents with significant reduction in angiographic binary restenosis, resulting in significantly less need for target lesion and target vessel revascularization.

Key words: angioplasty • coronary disease • stents • total coronary occlusions

Related Article:

Issue Highlights
Circulation 2006 114: 869. [Full Text]

This article has been cited by other articles:

				H. Kelbaek, L. Klovgaard, S. Helqvist, J. F. Lassen, L. R. Krusell, T. Engstrom, H. E. Botker, E. Jorgensen, K. Saunamaki, S. Aljabbari, et al. Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions: 3-Year Results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) Trial J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2011 - 2016. [Abstract] [Full Text] [PDF]

				H. V. Anderson Drug-Eluting Stents: Life Insurance With a Better Death Benefit J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2025 - 2027. [Full Text] [PDF]

				K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention. J. Am. Coll. Cardiol., February 19, 2008; 51(7): 701 - 707. [Abstract] [Full Text] [PDF]

				C. L. Grines Off-label use of drug-eluting stents putting it in perspective. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 615 - 617. [Full Text] [PDF]

				American College of Cardiology/American Heart Asso, 2007 Writing Group to Review New Evidence and Upda, S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, and D. O. Williams 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention J. Am. Coll. Cardiol., January 15, 2008; 51(2): 172 - 209. [Full Text] [PDF]

				S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, D. O. Williams, 2005 WRITING COMMITTEE MEMBERS, S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee Circulation, January 15, 2008; 117(2): 261 - 295. [Full Text] [PDF]

				J. D. Abbott, M. R. Voss, M. Nakamura, H. A. Cohen, F. Selzer, K. E. Kip, H. A. Vlachos, R. L. Wilensky, and D. O. Williams Unrestricted Use of Drug-Eluting Stents Compared With Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood Institute Dynamic Registry J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2029 - 2036. [Abstract] [Full Text] [PDF]

				J. Daemen and P. W. Serruys Drug-Eluting Stent Update 2007: Part II: Unsettled Issues Circulation, August 21, 2007; 116(8): 961 - 968. [Full Text] [PDF]

				F. Airoldi, A. Colombo, N. Morici, A. Latib, J. Cosgrave, L. Buellesfeld, E. Bonizzoni, M. Carlino, U. Gerckens, C. Godino, et al. Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment Circulation, August 14, 2007; 116(7): 745 - 754. [Abstract] [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., July 17, 2007; 50(3): 270 - 285. [Full Text] [PDF]

				H. V. Anderson, R. W. Smalling, and T. D. Henry Drug-Eluting Stents for Acute Myocardial Infarction J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1931 - 1933. [Full Text] [PDF]

				A. Prasad, C. S. Rihal, R. J. Lennon, H. J. Wiste, M. Singh, and D. R. Holmes Jr Trends in Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusions: A 25-Year Experience From the Mayo Clinic J. Am. Coll. Cardiol., April 17, 2007; 49(15): 1611 - 1618. [Abstract] [Full Text] [PDF]

				A. Kastrati, J. Mehilli, J. Pache, C. Kaiser, M. Valgimigli, H. Kelbaek, M. Menichelli, M. Sabate, M. J. Suttorp, D. Baumgart, et al. Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents N. Engl. J. Med., March 8, 2007; 356(10): 1030 - 1039. [Abstract] [Full Text] [PDF]

				Minerva BMJ, September 9, 2006; 333(7567): 558 - 558. [Full Text] [PDF]